Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus HYDROCORTISONE IN ABSORBASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus HYDROCORTISONE IN ABSORBASE.
EOHILIA vs HYDROCORTISONE IN ABSORBASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
Topical: Apply a thin layer to affected area 2-4 times daily.
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Category C
Category D/X
Corticosteroid
Corticosteroid